Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 12/20 | 0.55 |
| ▸ | MMP2 | P08253 | 9/20 | 0.55 |
| ▸ | MMP1 | P03956 | 18/20 | 0.54 |
| ▸ | MMP3 | P08254 | 10/20 | 0.51 |
| ▸ | MMP7 | P09237 | 7/20 | 0.51 |
| ▸ | MMP9 | P14780 | 7/20 | 0.51 |
| ▸ | MMP8 | P22894 | 3/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.49 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.47 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221001 | 0.96 | MMP13 (0.56) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7225271 | 0.95 | MMP13 (0.55) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7219951 | 0.95 | MMP13 (0.55) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7227440 | 0.95 | MMP13 (0.55) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7227317 | 0.95 | MMP13 (0.55) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7226571 | 0.95 | MMP13 (0.55) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7227567 | 0.95 | MMP13 (0.55) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7220063 | 0.94 | MMP13 (0.56) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7226106 | 0.93 | MMP13 (0.53) | MMP13ADAM17MMP2MMP1MMP3 | |
| SCHEMBL7224908 | 0.93 | MMP13 (0.53) | MMP13ADAM17MMP2MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | claimed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | claimed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP13 8/4885ADAM17 41/4885MMP2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.